Alatoxin B1 promotes cell growth and invasion in hepatocellular carcinoma HepG2 cells through H19 and E2F1

Asian Pacific Journal of Cancer Prevention

Volumn 15, Issue 6, 2014, Pages 2565-2570

  Lv, Jun ^a   Yu, Ya Qun ^b   Li, Shu Qun ^b   Luo, Liang ^a   Wang, Qian ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b GUILIN MEDICAL UNIVERSITY   (China)

Author keywords

AFB1; Cell growth and invasion; E2F1; H19; Hepatocellular carcinoma

Indexed keywords

AFLATOXIN B1; E2F1 PROTEIN, HUMAN; H19 LONG NON-CODING RNA; LONG UNTRANSLATED RNA; MESSENGER RNA; POISON; SMALL INTERFERING RNA; TRANSCRIPTION FACTOR E2F1;

ANTAGONISTS AND INHIBITORS; APOPTOSIS; CARCINOMA, HEPATOCELLULAR; CELL MOTION; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; DRUG EFFECTS; GENE EXPRESSION REGULATION; GENETICS; HEPG2 CELL LINE; HUMAN; LIVER NEOPLASMS; METABOLISM; PATHOLOGY; REAL TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; WESTERN BLOTTING;

AFLATOXIN B1; APOPTOSIS; BLOTTING, WESTERN; CARCINOMA, HEPATOCELLULAR; CELL MOVEMENT; CELL PROLIFERATION; CHROMATIN IMMUNOPRECIPITATION; E2F1 TRANSCRIPTION FACTOR; GENE EXPRESSION REGULATION, NEOPLASTIC; HEP G2 CELLS; HUMANS; LIVER NEOPLASMS; POISONS; REAL-TIME POLYMERASE CHAIN REACTION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, LONG NONCODING; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 84899802505     PISSN: 15137368     EISSN: 2476762X     Source Type: Journal    
DOI: 10.7314/APJCP.2014.15.6.2565     Document Type: Article

References (30)

1. Ayed-Boussema I, Pascussi JM, Maurel P, et al (2012). Effect of alatoxin B1 on nuclear receptors PXR, CAR, and AhR and their target cytochromes P450 mRNA expression in primary cultures of human hepatocytes. Int J Toxicol, 31, 86-93.
2. Berteaux N, Lottin S, Monte D, et al (2005). H19 mRNA-like noncoding RNA promotes breast cancer cell proliferation through positive control by E2F1. J Biol Chem, 280, 29625-36.
3. Braconi C, Valeri N, Kogure T, et al (2011). Expression and functional role of a transcribed noncoding RNA with an ultraconserved element in hepatocellular carcinoma. Proc Natl Acad Sci USA, 108, 786-91.
4. Calin GA, Liu CG, Ferracin M, et al (2007). Ultraconserved regions encoding ncRNAs are altered in human leukemias and carcinomas. Cancer Cell, 12, 215-29.
5. Dugimont T, Montpellier C, Adriaenssens E, et al (1998). The H19 TATA-less promoter is eficiently repressed by wild-type tumor suppressor gene product p53. Oncogene, 16, 2395-401.
6. Dyson N (1994). pRB, p107 and the regulation of the E2F transcription factor. J Cell Sci Suppl, 18, 81-7.
7. Dyson N (1998). The regulation of E2F by pRB-family proteins. Genes Dev, 12, 2245-62.
8. Eaton DL, Gallagher EP (1994). Mechanisms of aflatoxin carcinogenesis. Annu Rev Pharmacol, 34, 135-72.
9. Fang Y, Feng Y, Wu T, et al (2013). Alatoxin B1 negatively regulates Wnt/ß-catenin signaling pathway through activating miR-33a. PLoS One, 8, 73004.
10. Fellig Y, Ariel I, Ohana P, et al (2005). H19 expression in hepatic metastases from a range of human carcinomas. J Clin Pathol, 58, 1064-8.
11. Feng Y, Xue WJ, Li P, et al (2012). RASSF1A hypermethylation is associated with alatoxin B1 and polycyclic aromatic hydrocarbon exposure in hepatocellular carcinoma. Hepatogastroenterol, 59, 1883-8.
12. Fry CJ, Pearson A, Malinowski E, et al (1999). Activation of the murine dihydrofolate reductase promoter by E2F1. A requirement for CBP recruitment. J Biol Chem, 274, 15883-91.
13. Gabory A, Ripoche MA, Yoshimizu T, et al (2006). The H19 gene: regulation and function of a non-coding RNA. Cytogenet Genome Res, 113, 188-93.
14. Giannoukakis N, Deal C, Paquette J, et al (1993). Parental genomic imprinting of the human IGF2 gene. Nat Genet, 4, 98-101.
15. Hanioka N, Nonaka Y, Saito K, et al (2012). Effect of alatoxin B1 on UDP-glucuronosyltransferase mRNA expression in HepG2 cells. Chemosphere, 89, 526-9.
16. Hibi K, Nakamura H, Hirai A, et al (1996). Loss of H19 imprinting in esophageal cancer. Cancer Res, 56, 480-2.
17. IARC (2002). Some traditional herbal medicines, some mycotoxins, Naphthalene and Styrene. IARC Press, Lyon.
18. Khaitan D, Dinger ME, Mazar J, et al (2011). The melanoma- upregulated long noncoding RNA SPRY4-IT1 modulates apoptosis and invasion. Cancer Res, 71, 3852-62.
19. Lottin S, Adriaenssens E, Dupressoir T, et al (2002). Overexpression of an ectopic H19 gene enhances the tumorigenic properties of breast cancer cells. Carcinogenesis, 23, 1885-95.
20. Luo JH, Ren B, Keryanov S, et al (2006). Transcriptomic and genomic analysis of human hepatocellular carcinomas and hepatoblastomas. Hepatol, 44, 1012-24.
21. Matouk IJ, DeGroot N, Mezan S, et al (2007). The H19 non- coding RNA is essential for human tumor growth. PLoS One, 2, 845.
22. McLean M, Dutton MF (1995). Cellular interactions and metabolism of alatoxin: an update. Pharmacol Ther, 65, 163-92.
23. Ohtani K (1999). Implication of transcription factor E2F in regulation of DNA replication. Front Biosci, 4, 793-804.
24. Oyagbemi AA, Azeez OI, Saba AB (2010). Hepatocellular carcinoma and the underlying mechanisms. Afr Health Sci, 10, 93-8.
25. Panzitt K, Tschernatsch MM, Guelly C, et al (2007). Characterization of HULC, a novel gene with striking up- regulation in hepatocellular carcinoma, as noncoding RNA. Gastroenterol, 132, 330-42.
26. Yang C, Fan J, Zhuang Z, et al (2013). The role of NAD+- dependent isocitrate dehydrogenase 3 subunit a in AFB1 induced liver lesion. Toxicol Lett, 13, 01389-1.
27. Yang Z, Zhou L, Wu LM, et al (2011). Overexpression of long non-coding RNA HOTAIR predicts tumor recurrence in hepatocellular carcinoma patients following liver transplantation. Ann. Surg. Oncol, 18, 1243-50.
28. Zemel S, Bartolomei MS, Tilghman SM (1992). Physical linkage of two mammalian imprinted genes, H19 and insulin-like growth factor 2. Nat Genet, 2, 61-5.
29. Zhang Y, Tycko B (1992). Monoallelic expression of the human H19 gene. Nat Genet, 1, 40-4.
30. Zwicker J, Müller R (1997). Cell-cycle regulation of gene expression by transcriptional repression. Trends Genet, 13, 3-6.